Control | L-NAME | L-NAME+L-arginine | ||||
pD2 | Emax % | pD2 | Emax % | pD2 | Emax % | |
LCV ≤10−3 M# | 6.1±0.19 (9) | -10±1.5 (9) | -1±1.6* (9) | NA | NA | |
SCV ≤10−3 M# | 6.0±0.21 (6) | -8±2.5 (6) | 0±0* (6) | NA | NA | |
LCV ≥10−2 M# | 2.3±0.03 (9)+ | 12±2.0 (9)+ | 2.4±0.02 9) | 19±1.9 (9)* | NA | NA |
SCV ≥10−2 M# | 2.3±0.02 (6)+ | 10±1.2 (6)+ | 2.3±0.03 (6) | 19±3.6 (6)* | NA | NA |
ACV# | 5.6±0.23 (5)§ | 36±4.4 (5)§ | 5.7±0.18 (5) | 38±3.9 (5) | NA | NA |
DNV# | 5.7±0.23§ (6) | 58±2.4§ (6) | 5.9±3.6 (6) | 55±6.2 (6) | NA | NA |
SPV# | 4.9±0.12 (8)§ | 35±2.1 (8)§ | 5.2±0.10 (8) | 34±4.2 (8) | NA | NA |
LCV¶ | 4.7±0.14 (13)+ | -38±2.0 (13)+ | 4.5±0.19 (5) | -11±2.7 (5)* | 4.7±0.19 (5) | -33±2.8 (5)ƒ |
SCV¶ | 4.9±0.21 (12)+ | -39±3.5 (12)+ | 4.8±0.28 (6) | -8±2.3 (6)* | 5.1±0.20 (5) | -35±4.5 (5)ƒ |
Data are presented as mean±sem (n). L-NAME: nitro-L-arginine-methyl-ester 1×10-5 M; LCV: lateral collecting vein; SCV: septal collecting vein; ACV: anterior collecting vein; DNV: dorsal nasal vein; SPV: sphenopalatine vein; NA: not available. #: vascular segment at resting tension; ¶: vascular segment at raised tone; +: p<0.05 versus LCV and SCV at ≤1×10-3 M ACh at resting tension; §: p<0.05 versus LCV and SCV at ≥1×10-2 M ACh at resting tension. ƒ: p<0.05 versus L-NAME-treated group. *: p<0.05 versus control group. L-arginine was used at a concentration of 3×10-2 M.